Summary
Peripartum cardiomyopathy is a rare dilated cardiomyopathy occurring in late pregnancy or early postpartum, presenting with heart failure due to reduced ejection fraction (LVEF < 45%) in women without prior heart disease. Risk factors include advanced maternal age, African descent, multiple gestation, and hypertensive disorders. Diagnosis requires exclusion of other causes, and management follows standard heart failure therapy adapted for pregnancy. Prognosis is variable, with high morbidity, mortality, and risk of recurrence.
Definition
Peripartum cardiomyopathy is a rare, potentially life-threatening form of dilated cardiomyopathy characterized by the development of idiopathic heart failure with reduced ejection fraction (HFrEF) in late pregnancy or within five months postpartum. It occurs in women with no prior structural heart disease, and diagnosis requires exclusion of other causes of heart failure
Epidemiology and Risk Factors
The incidence of PPCM is estimated at 1–4 per 4,000 deliveries. It is more common among African American women, who account for over 40% of cases. Risk factors include maternal age > 30 years, multiple gestation pregnancy, hypertensive disorders of pregnancy (particularly preeclampsia), prolonged use of beta-adrenergic agonists for tocolysis, and poor nutritional status.
Pathophysiology
The exact mechanism remains unclear, but PPCM is believed to be multifactorial, involving hormonal, metabolic, oxidative, and angiogenic imbalances. Contributing factors include genetic predisposition, viral infections, autoimmune processes, and nutritional deficiencies. The hallmark finding is left ventricular systolic dysfunction with an ejection fraction < 45%
Clinical Features
PPCM usually presents in the last month of pregnancy or, more commonly, within the first month postpartum. Symptoms overlap with normal pregnancy but often reflect heart failure, including dyspnea, orthopnea, peripheral edema, and fatigue. Severe cases may present with cardiogenic shock or thromboembolic events.
Diagnosis
PPCM is a diagnosis of exclusion. Echocardiography is essential, showing reduced left ventricular ejection fraction (< 45%), variable ventricular dilatation, biatrial enlargement, functional mitral/tricuspid regurgitation, pulmonary hypertension, or ventricular thrombus. Supportive findings may include cardiomegaly on chest x-ray, elevated BNP or troponin, and nonspecific ECG changes.
Differential diagnoses include severe preeclampsia, myocardial infarction, Takotsubo cardiomyopathy, pulmonary embolism, amniotic fluid embolism, pneumonia, and acute lung injury.
Management
Treatment parallels standard HFrEF management but must consider pregnancy and lactation safety. Multidisciplinary care is crucial.
-
Acute decompensation: Stabilization, diuretics, vasodilators, and oxygen; cesarean delivery may be required if maternal status deteriorates.
-
Chronic therapy: Guideline-directed medical therapy for HFrEF, modified for pregnancy/lactation.
-
Anticoagulation: Indicated for patients with LVEF ≤ 30–35% or confirmed thromboembolic events. Heparin (UFH/LMWH) is preferred during pregnancy; warfarin may be used postpartum.
-
Delivery: Vaginal delivery is generally safe if the patient is stable; urgent cesarean is reserved for refractory cases.
- Breastfeeding: Generally safe in stable women, but should be delayed in acute decompensation.
Prognosis
Mortality remains high (≥ 20%). Recovery of cardiac function occurs in 50–70% of women within 3–6 months, especially when baseline LVEF is > 30%. However, 30–50% may have persistent dysfunction, and recurrence occurs in 20–50% of subsequent pregnancies. Women with unresolved dysfunction are advised to avoid future pregnancies.
احصل على التجربة الكاملة
اشترك للوصول لفيديوهات الشرح التفصيلي والبطاقات التعليمية التفاعلية وأسئلة الممارسة مع تتبع التقدم.